Inhibitors
Cat.No. | Name | Information |
---|---|---|
M1721 | AZD4547 | AZD4547 is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. |
M1840 | BGJ398 (Infigratinib) | BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
M21498 | Bemarituzumab | Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). |
M20223 | WAY-625530 | WAY-625530 is a Fibroblast Growth Factor Receptor 1 Kinase inhibitor. |
M20221 | WAY-621856 | WAY-621856 is a FGFR inhibitor. |
M20193 | WAY-603814 | WAY-603814 is a FGFR1 inhibitor |
M20183 | WAY-600868 | WAY-600868 is a FGFR3 inhibitor. |
M20165 | WAY-353890 | WAY-353890 is a inhibitor of protein kinase FGFR1 |
M20050 | WAY-272449 | WAY-272449 is a FGFR1 inhibitor. |
M20048 | WAY-272130 | WAY-272130 is a FGFR1 inhibitor. |
M20039 | WAY-270599 | WAY-270599 is a FGFR1 inhibitor |
M14896 | Rogaratinib | Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. |
M14895 | Infigratinib phosphate | Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. |
M14894 | Ferulic acid sodium | Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. |
M13357 | EOC317 | EOC317 (ACTB-1003) is an orally available kinase inhibitor that inhibits FGFR1, VEGFR2, and tie-2 with IC50 values of 6,2, and 4 nM, respectively. |
M10737 | PRN1371 | PRN1371 is a highly selective and potent inhibitor of FGFR1-4 and CSF1R against FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R IC50 The values are 0.6, 1.3, 4.1, 19.3, and 8.1 nM, respectively. |
M10590 | Alofanib (RPT835) | Alofanib (RPT835) is a novel selective allosteric inhibitor of FGFR2 and has a dramatic inhibitory effect with IC50 <10 nM on FGF2-induced phoshphorylation of FRS2a in KATO III cells. |
M10518 | ASP5878 | ASP5878 is a novel selective FGFR inhibitor with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3 and 4, respectively. |
M10048 | PF-05231023 | PF-05231023 is an FGF21-receptor agonist, it is also a potential treatment for T2DM. |
M10026 | Futibatinib (TAS-120) | Futibatinib (TAS-120) is an oral bioavailable, highly selective and irreversible FGFR inhibitor with IC50 of 3.9, 1.3, 1.6 and 8.3 nM against the four FGFR 1-4 subtypes, respectively. Futibatinib inhibited mutant and wild-type FGFR2 with IC50 similarity (wild-type FGFR2=0.9 nM; V5651 = 1 to 3 nM; N550H = 3.6 nM. E566G = 2.4 nM). |
M9715 | Erdafitinib | Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity. |
M9596 | Pemigatinib | Pemigatinib (INCB054828) is an orally effective, selective FGFR inhibitor with IC50 values of 0.4 nM, 0.5 nM, 1.2 nM, and 30 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.Pemigatinib exhibited anti-tumor activity in mouse xenograft models with FGFR1, FGFR2, or FGFR3-altered human tumors in a mouse xenograft model exhibiting antitumor activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.